| Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial G Van Assche, C Magdelaine–Beuzelin, G d'Haens, F Baert, M Noman, ... Gastroenterology 134 (7), 1861-1868, 2008 | 587 | 2008 |
| Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output S Dupuis-Girod, I Ginon, JC Saurin, D Marion, E Guillot, E Decullier, ... Jama 307 (9), 948-955, 2012 | 404 | 2012 |
| Infliximab pharmacokinetics in inflammatory bowel disease patients D Ternant, A Aubourg, C Magdelaine-Beuzelin, D Degenne, H Watier, ... Therapeutic drug monitoring 30 (4), 523-529, 2008 | 225 | 2008 |
| Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases E Ducourau, D Mulleman, G Paintaud, DC Miow Lin, F Lauféron, ... Arthritis research & therapy 13, 1-7, 2011 | 201 | 2011 |
| Behavior and serotonergic disorders in rats exposed prenatally to valproate: a model for autism D Dufour-Rainfray, P Vourc’h, AM Le Guisquet, L Garreau, D Ternant, ... Neuroscience letters 470 (1), 55-59, 2010 | 193 | 2010 |
| An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab D Ternant, D Mulleman, D Degenne, S Willot, JM Guillaumin, H Watier, ... Therapeutic drug monitoring 28 (2), 169-174, 2006 | 146 | 2006 |
| Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20 D Daydé, D Ternant, M Ohresser, S Lerondel, S Pesnel, H Watier, ... Blood, The Journal of the American Society of Hematology 113 (16), 3765-3772, 2009 | 136 | 2009 |
| Pharmacokinetics and concentration–effect relationships of therapeutic monoclonal antibodies and fusion proteins D Ternant, G Paintaud Expert opinion on biological therapy 5 (sup1), S37-S47, 2005 | 136 | 2005 |
| Cetuximab pharmacokinetics influences progression-free survival of metastatic colorectal cancer patients N Azzopardi, T Lecomte, D Ternant, M Boisdron-Celle, F Piller, A Morel, ... Clinical Cancer Research 17 (19), 6329-6337, 2011 | 117 | 2011 |
| Clinical pharmacokinetics and pharmacodynamics of monoclonal antibodies approved to treat rheumatoid arthritis D Ternant, T Bejan-Angoulvant, C Passot, D Mulleman, G Paintaud Clinical pharmacokinetics 54 (11), 1107-1123, 2015 | 110 | 2015 |
| Relationship between inflammation and infliximab pharmacokinetics in rheumatoid arthritis D Ternant, E Ducourau, A Perdriger, A Corondan, B Le Goff, ... British journal of clinical pharmacology 78 (1), 118-128, 2014 | 94 | 2014 |
| Pharmacokinetics and concentration–effect relationship of adalimumab in rheumatoid arthritis D Ternant, E Ducourau, P Fuzibet, C Vignault, H Watier, T Lequerré, ... British Journal of Clinical Pharmacology 79 (2), 286-297, 2015 | 86 | 2015 |
| Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report M Tout, O Casasnovas, M Meignan, T Lamy, F Morschhauser, G Salles, ... Blood, The Journal of the American Society of Hematology 129 (19), 2616-2623, 2017 | 85 | 2017 |
| Exposure to abatacept or rituximab in the first trimester of pregnancy in three women with autoimmune diseases M Ojeda-Uribe, N Afif, E Dahan, L Sparsa, C Haby, J Sibilia, D Ternant, ... Clinical rheumatology 32, 695-700, 2013 | 79 | 2013 |
| Evidence for linkage disequilibrium between FcγRIIIa-V158F and FcγRIIa-H131R polymorphisms in white patients, and for an FcγRIIIa-restricted influence on the response to … J Lejeune, G Thibault, D Ternant, G Cartron, H Watier, M Ohresser Journal of Clinical Oncology 26 (33), 5489-5491, 2008 | 77 | 2008 |
| Therapeutic drug monitoring of eculizumab: rationale for an individualized dosing schedule P Gatault, G Brachet, D Ternant, D Degenne, G Récipon, C Barbet, ... MAbs 7 (6), 1205-1211, 2015 | 75 | 2015 |
| FcγRIIIa expression is not increased on natural killer cells expressing the FcγRIIIa-158V allotype N Congy-Jolivet, A Bolzec, D Ternant, M Ohresser, H Watier, G Thibault Cancer research 68 (4), 976-980, 2008 | 71 | 2008 |
| IgG1 allotypes influence the pharmacokinetics of therapeutic monoclonal antibodies through FcRn binding D Ternant, C Arnoult, M Pugnière, C Dhommée, D Drocourt, E Perouzel, ... The Journal of Immunology 196 (2), 607-613, 2016 | 67 | 2016 |
| The underlying inflammatory chronic disease influences infliximab pharmacokinetics C Passot, D Mulleman, T Bejan-Angoulvant, A Aubourg, S Willot, ... MAbs 8 (7), 1407-1416, 2016 | 65 | 2016 |
| Influence of methotrexate on infliximab pharmacokinetics and pharmacodynamics in ankylosing spondylitis D Ternant, D Mulleman, F Lauféron, C Vignault, E Ducourau, D Wendling, ... British journal of clinical pharmacology 73 (1), 55-65, 2012 | 65 | 2012 |
Nicolas AzzopardiINRAe UMR85/CNRS UMR7247 - PRC.在 cnrs.fr 的电子邮件经过验证
Nicolas AzzopardiINRAe UMR85/CNRS UMR7247 - PRC.在 cnrs.fr 的电子邮件经过验证